KR20240019214A - 브루톤 티로신 키나제의 억제제 및 이의 사용 방법 - Google Patents

브루톤 티로신 키나제의 억제제 및 이의 사용 방법 Download PDF

Info

Publication number
KR20240019214A
KR20240019214A KR1020247000043A KR20247000043A KR20240019214A KR 20240019214 A KR20240019214 A KR 20240019214A KR 1020247000043 A KR1020247000043 A KR 1020247000043A KR 20247000043 A KR20247000043 A KR 20247000043A KR 20240019214 A KR20240019214 A KR 20240019214A
Authority
KR
South Korea
Prior art keywords
alkyl
compound
formula iii
therapeutically effective
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247000043A
Other languages
English (en)
Korean (ko)
Inventor
스리람 발라수브라마니안
이보 코넬리센
예 구오
조슬린 에이치. 루
캐서린 이. 팩맨
제임스 알렉산더 파머
울리케 필리파르
나빈 라오
마크 에스. 티체노르
제니퍼 디. 베너블
존 제이.엠. 위너
신 미아오
Original Assignee
얀센 파마슈티카 엔브이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔브이 filed Critical 얀센 파마슈티카 엔브이
Publication of KR20240019214A publication Critical patent/KR20240019214A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020247000043A 2021-06-04 2022-06-02 브루톤 티로신 키나제의 억제제 및 이의 사용 방법 Pending KR20240019214A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196843P 2021-06-04 2021-06-04
US63/196,843 2021-06-04
PCT/IB2022/055154 WO2022254371A1 (en) 2021-06-04 2022-06-02 Inhibitors of bruton's tyrosine kinase and methods of their use

Publications (1)

Publication Number Publication Date
KR20240019214A true KR20240019214A (ko) 2024-02-14

Family

ID=82214195

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247000043A Pending KR20240019214A (ko) 2021-06-04 2022-06-02 브루톤 티로신 키나제의 억제제 및 이의 사용 방법

Country Status (14)

Country Link
US (1) US20230013755A1 (https=)
EP (1) EP4346834A1 (https=)
JP (1) JP2024520630A (https=)
KR (1) KR20240019214A (https=)
CN (1) CN117412753A (https=)
AU (1) AU2022284369A1 (https=)
BR (1) BR112023025459A2 (https=)
CA (1) CA3220015A1 (https=)
CL (2) CL2023003564A1 (https=)
IL (1) IL308951A (https=)
JO (1) JOP20230310A1 (https=)
MX (1) MX2023014435A (https=)
TW (1) TW202317127A (https=)
WO (1) WO2022254371A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11964976B1 (en) 2023-09-12 2024-04-23 King Faisal University Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-c][1,6]naphthyridines as CK2 inhibitors
US20250333398A1 (en) 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015008042A2 (pt) 2012-10-11 2017-07-04 Pharmacyclics Inc diagnósticos complementares para terapia com inibidor de quinase da família tec
MA40596B1 (fr) * 2014-08-11 2021-12-31 Acerta Pharma Bv Combinaisons thérapeutiques d'un inhibiteur de btk et d'un inhibiteur de bcl-2
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
WO2018103060A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use

Also Published As

Publication number Publication date
AU2022284369A1 (en) 2024-01-25
IL308951A (en) 2024-01-01
EP4346834A1 (en) 2024-04-10
BR112023025459A2 (pt) 2024-02-27
CL2024002895A1 (es) 2025-02-14
CA3220015A1 (en) 2022-12-08
CN117412753A (zh) 2024-01-16
CL2023003564A1 (es) 2024-06-21
TW202317127A (zh) 2023-05-01
WO2022254371A1 (en) 2022-12-08
US20230013755A1 (en) 2023-01-19
JOP20230310A1 (ar) 2023-11-29
MX2023014435A (es) 2024-03-08
JP2024520630A (ja) 2024-05-24

Similar Documents

Publication Publication Date Title
JP7795513B2 (ja) ブルトン型チロシンキナーゼ（Ｂｔｋ）の阻害剤の使用
KR20240019214A (ko) 브루톤 티로신 키나제의 억제제 및 이의 사용 방법
KR102666352B1 (ko) 티로신 키나제 억제제
US20160022683A1 (en) Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
US20240238291A1 (en) Combinations for treatment of cancer
KR20230109775A (ko) 브루톤 티로신 인산화효소(btk)의 억제제의 용도
JP2024138243A (ja) Ｂｔｋ阻害剤を含む製剤／組成物
KR20230007359A (ko) 메닌 억제제 및 cyp3a4 억제제의 조합물 및 그의 사용 방법
CN108779111B (zh) 结合脱氧胞苷激酶的化合物
CN108024996A (zh) 布鲁顿氏酪氨酸激酶抑制剂组合和其用途
JP2025063134A (ja) 化学療法抵抗性がんの組合せ処置
KR20220101099A (ko) C-c 케모카인 수용체 유형 4 길항제의 결정 형태 및 이의 용도
CA3223610A1 (en) Inhibitors of bruton's tyrosine kinase and methods of their use
HK40107411A (zh) 布鲁顿氏酪氨酸激酶抑制剂及其使用方法
EA051432B1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
HK40102175A (zh) 布鲁顿酪氨酸激酶的抑制剂及其使用方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240102

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250529

Comment text: Request for Examination of Application